Alliance A022102: Randomized phase III trial of mFOLFIRINOX +/- nivolumab vs. FOLFOX +/- nivolumab for first-line treatment of metastatic HER2-negative gastroesophageal adenocarcinoma (GEA).
- Citation:
- J Clin Oncol vol 41 (suppl 16) TPS4175
- Meeting Instance:
- ASCO 2023
- Year:
- 2023
- Type:
- Abstract
- Sub type:
- Poster Discussion
- Funding:
- NCTN
- Endpoint:
- No-Endpoint
- Analysis:
- Trial-Description-Only
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- epreprint
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- None
- Pharmas:
- Grants:
- U10CA180821, U10CA180882; U10CA180868 (ECOG-ACRIN); U10CA180868 (NRG);
- Corr. Author:
- Authors:
- Haeseong Park Susan Geyer Kelsey Klute Jonathan Bleeker Daniel King Matthew Strickland Austin Goodrich Destin Carlisle Ardaman Shergill Eileen O'Reilly Jeffrey Meyerhardt Manish A. Shah
- Networks:
- LAPS-IL057, LAPS-MA036, LAPS-NY016, NE003, NORTHWELL, NY018, SANFORD
- Study
- Alliance-A022102
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: